Gri Bio Inc. (GRI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
GRI Bio, Inc. GRI stock is trading on Tuesday with a strong session volume of 6.9 million compared to an average volume of 17.35K, as per data from Benzinga Pro.
UK residential rent rises are slowing but Grainger says demand remains strong
Grainger Plc (LSE:GRI) reported slower rental growth for recent months and said it expects further slowing in the coming year. The FTSE 250-listed private landlord, which owns around 12,000 homes, said rental growth was 6.3% in the year ending 30 September 2024 on a like-for-like basis.
Gri Bio Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EW Edward Woo Ascendiant Capital | 13,229.21 | $27,384.46 | $29,765.72 | $2,381.26 | 8.7% |
| JP Joseph Pantginis HC Wainwright & Co. | -4,319.94 | $217,237.86 | $9,719.87 | $207,517.99 | 95.53% |
Gri Bio Inc. (GRI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gri Bio Inc. ever had a stock split?
Gri Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | W. Marc Hertz CEO | NASDAQ (CM) Exchange | 3622AW502 CUSIP |
| US Country | 3 Employees | - Last Dividend | 26 Jan 2026 Last Split | - IPO Date |
Overview
GRI Bio, Inc. is a clinical-stage biopharmaceutical company with a focused mission to discover, develop, and bring to market therapies targeting diseases that lead to inflammatory, fibrotic, and autoimmune disorders within the United States. Initially known as Glycoregimmune, Inc., this innovative company was established in 2009 and is headquartered in La Jolla, California. Through its dedication to addressing unmet medical needs, GRI Bio is at the forefront of developing novel therapeutics for a range of severe and life-altering conditions.
Products and Services
- GRI-0621
An oral inhibitor targeting type 1 Natural Killer T (NKT) cells, GRI-0621 is GRI Bio's flagship product candidate. Currently in Phase II clinical trials, this promising therapy aims to treat severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. By inhibiting type 1 NKT cells, GRI-0621 has the potential to offer a novel approach in managing fibrosis and inflammation associated with these lung conditions.
- GRI-0803
This novel oral agonist targets type 2 Natural Killer T (NKT) cells and is in the preclinical development stage. GRI-0803 showcases GRI Bio's commitment to expanding its portfolio into the autoimmune disorder space. The therapeutic aim of GRI-0803 is to modulate the immune response in a way that could benefit patients suffering from a variety of autoimmune disorders, offering a new hope in the treatment landscape.
- Proprietary Library of 500+ Compounds
GRI Bio boasts a proprietary library of over 500 compounds, which serves as a valuable resource for ongoing discovery and development efforts. This extensive collection of compounds underpins the company's R&D strategy, facilitating the exploration and identification of novel therapeutic avenues across its focus areas of inflammatory, fibrotic, and autoimmune diseases.
- GRI-0124
Targeting the treatment of primary sclerosing cholangitis, GRI-0124 is another key component of GRI Bio's product pipeline. Currently in pre-clinical development, this candidate exemplifies the company's efforts in addressing rare and challenging diseases through innovative approaches and targeted therapies.
- GRI-0729
Also in pre-clinical development, GRI-0729 represents GRI Bio's dedication to broadening its impact by aiming to offer new treatments for diseases with significant unmet needs. While specific details of its therapeutic target are not disclosed, it adds depth to the company's diversified portfolio of promising early-stage developments.
